Cemsidomide in Combination With Elranatamab

A Phase 1B, Open-label, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
60 patients (estimated)
Tags
IKZF1/3
Trial Type
Treatment
Last Update
SparkCures ID
2219
NCT Identifier
NCT07280013

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.